ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Tuesday, October 28, 2025

11:15AM-11:30AM: Abstract Number: 1769

Classification of Relapses of Eosinophilic Granulomatosis with Polyangiitis After Two-Years of Treatment with Anti-Interleukin-5/Receptor Therapy

Abstracts: Vasculitis – ANCA-Associated (1764–1769)

11:15AM-11:30AM: Abstract Number: 1751

Disease activity, inflammation, and older age are associated with quantitative interstitial abnormalities in early RA: Results from a multicenter, prospective cohort study

Abstracts: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes I: Breathe (ILD/Pulmonary) (1746–1751)

11:15AM-11:30AM: Abstract Number: 1745

High Emotional Distress Predicts Suboptimal Cardiovascular Health Among Patients with Juvenile-Onset Lupus and Dermatomyositis: Longitudinal Analysis of the Lupus Erythematosus and Dermatomyositis Stress and Cardiovascular Health Cohort Study

Abstracts: Pediatric Rheumatology – Clinical II (1740–1745)

11:15AM-11:30AM: Abstract Number: 1733

Risk factors for the development of immune checkpoint inhibitor-related adverse events, including rheumatology-related presentations

Abstracts: Immunological Complications of Medical Therapy (1728–1733)

11:15AM-11:30AM: Abstract Number: 1757

Skin-to-Joint Immune Cell Migration and Synovial Reprogramming in Psoriatic Arthritis Onset

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Basic Science (1752–1757)

11:15AM-11:30AM: Abstract Number: 1763

Spatial Organization and Function of Disease-Associated Macrophages in Lupus Nephritis: Insights from Cross-Species Analyses

Abstracts: Systemic Lupus Erythematosus – Animal Models (1758–1763)

1:00PM-1:15PM: Abstract Number: 2597

Altered Tryptophan Metabolism in Neuropsychiatric Lupus: A Cluster Analysis to Identify Distinct Subgroups

Abstracts: Systemic Lupus Erythematosus – Etiology and Pathogenesis (2597–2602)

1:00PM-1:15PM: Abstract Number: 2591

Association Between Changes in Bone Quality Parameters and Inflammatory Ratios in Postmenopausal Women Treated With Romosozumab: A Retrospective Observational Study

Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (2591–2596)

1:00PM-1:15PM: Abstract Number: 2573

Impaired Humoral Response to Recombinant Herpes Zoster Vaccine in Rituximab Treated Autoimmune Rheumatic Diseases Patients: A Prospective Controlled Phase 4 Study

Abstracts: Infection-related Rheumatic Disease (2573–2578)

1:00PM-1:15PM: Abstract Number: 2579

Mutant COPA Permits Aberrant NETosis and Exacerbates Autoimmune Lung Disease

Abstracts: Innate Immunity (2579–2584)

1:00PM-1:15PM: Abstract Number: 2567

Temporal Trends in Cardiometabolic Multimorbidity Risk in Rheumatoid Arthritis: A National, Matched Cohort Study

Abstracts: Epidemiology & Public Health II (2567–2572)

1:00PM-1:15PM: Abstract Number: 2585

The effect of prophylactic colchicine use on gene expression in gout

Abstracts: Metabolic & Crystal Arthropathies – Basic & Clinical Science (2585–2590)

1:15PM-1:30PM: Abstract Number: 2568

Cardiovascular Risk Prediction in Systemic Lupus Erythematosus: Comparing the PREVENT and SLECRISK Models

Abstracts: Epidemiology & Public Health II (2567–2572)

1:15PM-1:30PM: Abstract Number: 2574

Differences in SARS-CoV-2 Antigen Persistence in Individuals with Systemic Autoimmune Rheumatic Diseases Compared to the General Population

Abstracts: Infection-related Rheumatic Disease (2573–2578)

1:15PM-1:30PM: Abstract Number: 2586

Estimated Carrier Prevalence of HLA-B*58:01 Across Diverse Populations in the US and Globally

Abstracts: Metabolic & Crystal Arthropathies – Basic & Clinical Science (2585–2590)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].